CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 2.73×, higher than 95% of its Biotechnology peers (median 0.09×)
- FinancialsAltman Z-Score -1.25: distress zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
440.34MEUR508.28M · vs all stocks (USD)
Revenue (TTM)
156.33MEUR180.45M · vs all stocks (USD)
Profit Margin
-88.30%vs Biotechnology peers
Beta
1.41xvs all stocks
52-Week Change
-19.25%vs all stocks
Market Capitalization
440.34MEUR508.28M · vs all stocks (USD)
Enterprise Value
488.40MEUR563.76M · vs all stocks (USD)
Forward P/E
8.24xvs Biotechnology peers
Price to Sales (TTM)
2.82xvs Biotechnology peers
Price to Book (MRQ)
5.01xvs Biotechnology peers
Enterprise to Revenue
3.12xvs Biotechnology peers
Enterprise to EBITDA
-5.96xvs Biotechnology peers
Gross Margin
15.28%vs Biotechnology peers
Profit Margin
-88.30%vs Biotechnology peers
Operating Margin
-76.67%vs Biotechnology peers
Return on Assets (TTM)
-14.54%vs Biotechnology peers
Return on Equity (TTM)
-109.57%vs Biotechnology peers
Revenue (TTM)
156.33MEUR180.45M · vs all stocks (USD)
Revenue per Share (TTM)
0.8970EURUpdated Jul 20, 2026Quarterly Revenue Growth
-37.20%vs Biotechnology peers
Gross Profit (TTM)
-39.51MEUR-45.61M · vs all stocks (USD)
EBITDA (TTM)
-81.88MEUR-94.51M · vs all stocks (USD)
Net Income (TTM)
-138.03MEUR-159.33M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-37.23%vs Biotechnology peers
Operating Cash Flow (TTM)
-45.06MEUR-52.01M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-31.01MEUR-35.79M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Jul 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
174.66MEURFY2025 · Dec 31, 2025Cost of Goods Sold
107.14MEURFY2025 · Dec 31, 2025Gross Profit
67.52MEURFY2025 · Dec 31, 2025Operating Income
-81.63MEUR-94.23M · vs all stocks (USD)
Pre-tax Income
-114.12MEURFY2025 · Dec 31, 2025Income Tax Expense
1.07MEURFY2025 · Dec 31, 2025Net Income
-115.19MEURFY2025 · Dec 31, 2025EBIT
-72.22MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-57.24MEURFY2025 · Dec 31, 2025Research & Development
85.30MEURFY2025 · Dec 31, 2025Selling, General & Administrative
74.68MEURFY2025 · Dec 31, 2025Other Operating Expenses
-11.20MEURFY2025 · Dec 31, 2025Non-operating Interest Income
1.80MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
41.90MEURFY2025 · Dec 31, 2025EPS (Basic)
-0.6800EURFY2025 · Dec 31, 2025EPS (Diluted)
-0.6800EURFY2025 · Dec 31, 2025Basic Shares Outstanding
168.18MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
168.18MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-115.19MEURFY2025 · Dec 31, 2025Operating Cash Flow
-48.13MEURFY2025 · Dec 31, 2025Free Cash Flow
-52.42MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
109.65MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-115.19MEURFY2025 · Dec 31, 2025Depreciation & Amortization
21.75MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
1.07MEURFY2025 · Dec 31, 2025Stock-based Compensation
9.53MEURFY2025 · Dec 31, 2025Other Non-cash Items
30.40MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
13.33MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.02MEURFY2025 · Dec 31, 2025Capital Expenditures
-4.29MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-61.00KEURFY2025 · Dec 31, 2025Net Acquisitions
0.00EURFY2025 · Dec 31, 2025Sale of Investments
841.00KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.45MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
174.40MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-174.34MEURFY2025 · Dec 31, 2025Common Dividends Paid
0.00EURFY2025 · Dec 31, 2025Other Financing Charges
1.00KEURFY2025 · Dec 31, 2025Net Financing Cash Flow
62.00KEURFY2025 · Dec 31, 2025Shares Outstanding
173.75MSharesUpdated Jul 20, 2026Float Shares
147.76MSharesUpdated Jul 20, 2026% Held by Insiders
10.72%vs all stocks
% Held by Institutions
24.41%vs all stocks
Total Cash (MRQ)
105.27MEUR121.51M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5910EURUpdated Jul 20, 2026Total Debt (MRQ)
209.50MEUR241.83M · vs all stocks (USD)
Total Debt to Equity (MRQ)
2.73xvs Biotechnology peers
Current Ratio (MRQ)
2.14xvs Biotechnology peers
Book Value per Share (MRQ)
0.4300EURUpdated Jul 20, 2026Total Assets
398.84MEUR460.37M · vs all stocks (USD)
Total Current Assets
222.54MEURFY2025 · Dec 31, 2025Total Liabilities
292.67MEURFY2025 · Dec 31, 2025Total Non-current Assets
176.30MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
199.33MEURFY2025 · Dec 31, 2025Total Current Liabilities
93.33MEURFY2025 · Dec 31, 2025Cash
109.65MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
109.65MEURFY2025 · Dec 31, 2025Accounts Receivable
27.73MEURFY2025 · Dec 31, 2025Inventory
50.23MEURFY2025 · Dec 31, 2025Accounts Payable
9.07MEURFY2025 · Dec 31, 2025Short-term Debt
20.64MEURFY2025 · Dec 31, 2025Deferred Revenue
432.00KEURFY2025 · Dec 31, 2025Other Current Liabilities
5.69MEURFY2025 · Dec 31, 2025Long-term Debt
186.60MEURFY2025 · Dec 31, 2025Other Non-current Liabilities
245.00KEURFY2025 · Dec 31, 2025Common Stock (Book)
26.03MEURFY2025 · Dec 31, 2025Retained Earnings
-679.12MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
106.17MEUR122.55M · vs all stocks (USD)
Treasury Stock
645.00KEURFY2025 · Dec 31, 202552-Week Low
2.11EURUpdated Jul 20, 202652-Week High
5.42EURUpdated Jul 20, 202652-Week Change
-19.25%vs all stocks
Beta
1.41xvs all stocks
50-Day MA
2.36EURUpdated Jul 20, 2026200-Day MA
3.43EURUpdated Jul 20, 2026Avg 10-Day Volume
404.44KSharesUpdated Jul 20, 2026Avg 30-Day Volume
418.37KSharesUpdated Jul 20, 2026Diluted EPS (TTM)
-0.8000EURUpdated Jul 20, 2026Other Income / Expense
6.76MEURFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 2.73×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 2.73Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 121,506,336.85Total Debt (USD): 241,829,517.216Debt-to-Equity: 2.73
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.14Altman Z-Score: -1.25
Financial Health
Altman Z-Score -1.25: distress zoneCritical
Altman Z-Score: -1.25
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sd Biosensor Inc.
Tier 1ProductionApproval-Gated PipelineRule
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Shen Lian Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ZJ Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Enovix Corporation
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp DeclineHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hyliion Holdings Corp.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp DeclineHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Microvision Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp DeclineHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC